ArticleJournal of virology2001
Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 92 citations in OpenAlex.
- Biomarkers in Detection of Hepatitis C Virus Infection.Pathogens (Basel, Switzerland) · 2024Review
- Hepatitis C Virus: 30 Years after Its Discovery.Cold Spring Harbor perspectives in medicine · 2019Review
- Progress toward approval of an HCV vaccine.Canadian liver journal · 2018Review
- Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding.Scientific reports · 2015Article
- Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.World journal of hepatology · 2015Review
- Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.Journal of virology · 2015Article
- The past, present and future of neutralizing antibodies for hepatitis C virus.Antiviral research · 2014Review
- Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity.Virologica Sinica · 2013Article
- Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.Hepatology (Baltimore, Md.) · 2011Article
- The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus.PLoS computational biology · 2009Article
- Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives.Viruses · 2009Article
- Adaptive immunity to hepatitis C virus.Viruses · 2009Article
- Development of hepatitis C virus vaccines: challenges and progress.Expert review of vaccines · 2009Review
- Article
- Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain.Journal of virology · 2008Article
- Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.World journal of gastroenterology · 2007Review
- Hepatocellular carcinoma: therapy and prevention.World journal of gastroenterology · 2005Review
- Article
- Underwhelming the immune response: effect of slow virus growth on CD8+-T-lymphocyte responses.Journal of virology · 2004Article
- Cross-genotype immunity to hepatitis C virus.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naturally occurring hepatitis C virus (HCV) infection has long been thought to induce a weak immunity which is insufficient to protect an individual from subsequent infections and has cast doubt on the ability to develop effective vaccines. A series of intrahepatic genetic inoculations (IHGI) with type 1a HCV RNA were performed in a chimpanzee to determine whether a form of genetic immunization might stimulate protective immunity. We demonstrate that the chimpanzee not only developed protective immunity to the homologous type 1a RNA after rechallenge by IHGI but was also protected from chronic HCV infection after sequential rechallenge with 100 50% chimpanzee infectious doses of a heterologous type 1a (H77) and 1b (HC-J4) whole-virus inoculum. These results offer encouragement to pursue the development of HCV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.